<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="135982">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01651780</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol No. TMC-BIV-11-02</org_study_id>
    <secondary_id>2012‐000632‐26</secondary_id>
    <nct_id>NCT01651780</nct_id>
  </id_info>
  <brief_title>International, Multi-center, Open-label, Randomized Controlled Trial in Patients Undergoing TAVR to Determine the Treatment Effect (Both Safety and Efficacy) of Using Bivalirudin Instead of UFH.</brief_title>
  <acronym>BRAVO 2/3</acronym>
  <official_title>Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Medicines Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Medicines Company</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Germany: Ethics Commission</authority>
    <authority>Italy: Ethics Committee</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>Switzerland: Ethikkommission</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, open-label, randomized controlled trial.  All
      patients undergoing transfemoral TAVR at the participating centers will be eligible.  All
      sites will initiate enrolment with 2 feasibility roll-in bivalirudin treated patients and
      thereafter patients will be randomly assigned to either standard dosing of bivalirudin or
      UFH as control. The 2 roll-in cases per site will constitute the feasibility cohort that
      will be followed and analyzed separately.  Patients will undergo TAVR according to current
      standard of care practices at the treating centers. Use of antiplatelet agents pre, during,
      and post procedure, and possibly oral anticoagulants post procedure, will be according to
      the sites' standard practice. ALL available data will be collected in the eCRF prospectively
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be an international, multi-center, open-label, randomized controlled trial
      in patients undergoing TAVR. Following the conclusion of the roll-in phase of 2 patients per
      site, who will comprise the feasibility cohort of approximately 70 patients, 550 patients
      will be randomized to bivalirudin or UFH at approximately 35 centers. Informed consent will
      be obtained from patients meeting the inclusion criteria before the initiation of any
      study-specific procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Major Bleeding</measure>
    <time_frame>48h post or discharge</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The primary end point will be major bleeding defined as Bleeding Academic Research Consortium (BARC) type ≥3b at 48 hours or hospital discharge whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>48 hours post-procedure</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The secondary endpoints of this trial are: (1) Major bleeding according to additional scales (VARC, TIMI, GUSTO, ACUITY/HORIZONS); (2) Bleeding BARC ≥3; moderate bleeding BARC = 3a; minor bleeding (BARC type 1 and 2 and TIMI minor); (3) major adverse cardiac events (MACE) including death, non-fatal MI, and stroke; (4) the rates of the individual components of MACE; (5) transient ischemic attack; (6) acute kidney injury; (7) VARC major vascular complications; (8) acquired thrombocytopenia; (9) rate of new post-procedural atrial fibrillation/flutter; and (10) economic analysis of using bivalirudin in TAVR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">620</enrollment>
  <condition>Severe Aortic Stenosis</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Transcatheter Aortic Valve Replacement</condition>
  <condition>Aortic Valve Replacement</condition>
  <arm_group>
    <arm_group_label>Bivalirudin during Trans-Aortic Valve Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalirudin will be administered as a bolus and infusion. It is recommended that the bolus (0.75 mg/kg) be directly administered through the valve delivery sheath immediately following its successful delivery via percutaneous femoral access.  Systemic IV administration of the bolus dose is also acceptable. The bivalirudin intravenous infusion is initiated immediately after the bolus administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unfractionated heparin during Trans-Aortic Valve Replacement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of UFH should adhere to the standard institutional practice.  An ACT target ≥ 250 seconds is recommended</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Trans-Aortic Valve Replacement</intervention_name>
    <description>transcatheter aortic valve replacement (TAVR) procedures performed via the transfemoral approach</description>
    <arm_group_label>Bivalirudin during Trans-Aortic Valve Replacement</arm_group_label>
    <arm_group_label>Unfractionated heparin during Trans-Aortic Valve Replacement</arm_group_label>
    <other_name>TAVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  High risk (Euroscore ≥18, or considered inoperable) for surgical aortic valve
             replacement

          -  Undergoing TAVR via transfemoral arterial access

          -  Provide written informed consent before initiation of any study related procedures

        Exclusion Criteria:

          -  Any known contra‐indication to the use of bivalirudin (except presence of severe
             renal impairment [GFR&lt;30 ml/min] since these patients will be included in the trial
             or UFH

          -  Refusal to receive blood transfusion

          -  Mechanical valve (any location) or mitral bioprosthetic valve

          -  Extensive calcification of the common femoral artery, or minimal luminal diameter&lt;
             6.5 mm

          -  Use of elective surgical cut-down for transfemoral access

          -  Concurrent performance of percutaneous coronary intervention with TAVR

          -  International normalized ratio (INR) ≥ 2 on the day of TAVR procedure, or known
             history of bleeding diathesis

          -  History of hemorrhagic stroke, intracranial hemorrhage, intracerebral mass or
             aneurysm, or arteriovenous malformation

          -  Severe left ventricular dysfunction (left ventricular ejection fraction&lt;15%)

          -  Severe aortic regurgitation or mitral regurgitation (4+)

          -  Hemodynamic instability (e.g. requiring inotropic or IABP support) within 2 hours of
             the procedure

          -  Dialysis dependent

          -  Administration of thrombolytics, glycoprotein IIb/IIIa inhibitors, or warfarin in the
             3 days prior to the procedure

          -  Acute myocardial infarction, major surgery or any therapeutic cardiac procedure
             (other than balloon aortic valvuloplasty) within 30 days

          -  Percutaneous coronary intervention within 30 days

          -  Upper gastrointestinal or genitourinary bleed within 30 days

          -  Stroke or transient ischemic attack within 30 days

          -  Any surgery or biopsy within 2 weeks

          -  Administration of:

               -  UFH within 30 minutes of the procedure

               -  Enoxaparin within 8 hours of the procedure

               -  Fondaparinux or other LMWHs within 24 hours of the procedure

               -  Dabigatran, rivaroxaban or other oral anti-Xa or antithrombin agent within 48
                  hours of the procedure

               -  Thrombolytics, GPI, or warfarin within 72 hours of the procedure

          -  Absolute contraindications or allergy that cannot be pre-medicated to iodinated
             contrast

          -  Contraindications or allergy to aspirin or clopidogrel

          -  Known or suspected pregnant women, or nursing mothers. Women of child‐bearing
             potential will be asked if they are pregnant and will be tested for pregnancy

          -  Previous enrolment in this study

          -  Treatment with other investigational drugs or devices within the 30 days preceding
             enrollment or planned use of other investigational drugs or devices before the
             primary endpoint of this study has been reached Patients excluded for any of the
             above reasons may be re-screened for participation at any time if the exclusion
             characteristic has changed.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Privé Jacques Cartier</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prodromos Anthopoulos, MD</last_name>
    <role>Study Director</role>
    <affiliation>The Medicines Company</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eberhardt Grube, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eberhardt Grube, MD</last_name>
    <email>grubeE@aol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thierry Lefevre, MD</last_name>
    <email>t.lefevre@angio-icps.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Paul´s Hospital Providence Health Care</name>
      <address>
        <city>Vancouver</city>
        <zip>V6Z1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <state>Cedex9</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum München</name>
      <address>
        <city>München</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Hengstenberg, MD</last_name>
      <email>hengstenberg@dhm.mhn.de</email>
    </contact>
    <investigator>
      <last_name>Christian Hengstenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele U.O. Cardiologia Interventistica</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Colombo, MD</last_name>
      <email>colombo.antonio@hsr.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jur ten Berg, MD</last_name>
      <email>j.ten.berg@antoniusziekenhuis.nl</email>
    </contact>
    <investigator>
      <last_name>Jur ten Berg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Windecker, MD</last_name>
      <email>stephan.windecker@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Stephan Windecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>East Sussex</state>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Hildick-Smith, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Hildick-Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 6, 2014</lastchanged_date>
  <firstreceived_date>July 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transcatheter aortic valve replacement</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>aortic valve insufficiency</keyword>
  <keyword>severe aortic stenosis</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bivalirudin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
